Lupin has launched Olmesartan Medoxomil tablets, a hypertension drug, in the US market.
The company has launched the tablets in strengths of 5 mg, 20 mg and 40 mg after having received an approval from the United States Food and Drug Administration (FDA) earlier, Lupin Ltd said in a statement today.
The Mumbai-based company’s product is the generic equivalent of Daiichi Sankyo Inc’s Benicar tablets which is indicated for the treatment of hypertension.
As per IMS MAT data for July 2017, Benicar tablets had US sales of $681 million.
Lupin shares were trading 0.15 per cent down at Rs 992 on the BSE.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.